Compare · ALC vs RXST
ALC vs RXST
Side-by-side comparison of Alcon Inc. (ALC) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALC and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- ALC is the larger of the two at $33.27B, about 171.3x RXST ($194.2M).
- Over the past year, ALC is down 11.9% and RXST is down 45.3% - ALC leads by 33.4 points.
- ALC has been more active in the news (3 items in the past 4 weeks vs 1 for RXST).
- Both have 25 recent analyst ratings on file.
- Company
- Alcon Inc.
- RxSight Inc.
- Price
- -
- -
- Market cap
- $33.27B
- $194.2M
- 1M return
- +1.52%
- -15.15%
- 1Y return
- -11.87%
- -45.30%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2021
- News (4w)
- 3
- 1
- Recent ratings
- 25
- 25
Alcon Inc.
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; and EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, including devices and over-the-counter products for dry eye, over-the-counter products for contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. Alcon, Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest ALC
- FDA Approves Alcon’s BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
- Barclays initiated coverage on Alcon with a new price target
- Introducing Systane® PRO PRESERVATIVE-FREE: Alcon’s Longest Lasting, Triple-Action Formula for up to 12 Hours of Dry Eye Symptom Relief
- Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control
- Alcon Prices EUR 500 Million Senior Notes Offering
- Alcon downgraded by BNP Paribas Exane with a new price target
- SEC Form 6-K filed by Alcon Inc.
- New Product Launches and Strong Commercial Execution Drive Alcon's Second-Quarter 2026 Growth
- Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs
- SEC Form SD filed by Alcon Inc.
Latest RXST
- K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world
- Officer Weinberg Eric exercised 35,168 shares at a strike of $4.34, increasing direct ownership by 18% to 235,516 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Wilterding Mark
- SEC Form 4 filed by Officer Weinberg Eric
- SEC Form 4 filed by Chief Medical Officer Kurtz Ronald M Md
- SEC Form 4 filed by Chief Operating Officer Goldshleger Ilya
- Amendment: SEC Form SC TO-I/A filed by RxSight Inc.
- Chief Medical Officer Kurtz Ronald M Md converted options into 13,425 shares and sold $35,496 worth of shares (5,100 units at $6.96), increasing direct ownership by 13% to 71,775 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Wilterding Mark converted options into 20,441 shares and sold $54,044 worth of shares (7,765 units at $6.96), increasing direct ownership by 102% to 25,049 units (SEC Form 4) (tax withholding)
- Chief Operating Officer Goldshleger Ilya converted options into 5,370 shares and sold $14,205 worth of shares (2,041 units at $6.96), increasing direct ownership by 4% to 81,509 units (SEC Form 4) (tax withholding)